Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance
- PMID: 19635647
- DOI: 10.1016/j.ctrv.2009.06.005
Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance
Abstract
Increased chemo-resistance and radio-resistance of cancer cells is a major obstacle in the treatment and management of malignant cancers. An important mechanism that underlies the development of such therapeutic resistance is that cancer cells recognize DNA lesions induced by DNA-damaging agents and by ionizing radiation, and repair these lesions by activating various DNA repair pathways. Therefore, Use of pharmacological agents that can inhibit certain DNA repair pathways in cancer cells has the potential for enhancing the targeted cytotoxicity of anticancer treatments and reversing the associated therapeutic resistance associated with DNA repair; such agents, offering a promising opportunity to achieve better therapeutic efficacy. Here we review the major DNA repair pathways and discuss recent advances in the development of novel inhibitors of DNA repair pathways; many of these agents are under preclinical/clinical investigation.
Similar articles
-
Targeting DNA repair as a promising approach in cancer therapy.Eur J Cancer. 2007 Aug;43(12):1791-801. doi: 10.1016/j.ejca.2007.05.003. Epub 2007 Jun 27. Eur J Cancer. 2007. PMID: 17588740 Review.
-
Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics.Semin Oncol. 2009 Apr;36(2 Suppl 1):S42-51. doi: 10.1053/j.seminoncol.2009.02.004. Semin Oncol. 2009. PMID: 19393835
-
DNA repair pathways and their implication in cancer treatment.Cancer Metastasis Rev. 2010 Dec;29(4):677-85. doi: 10.1007/s10555-010-9258-8. Cancer Metastasis Rev. 2010. PMID: 20821251 Review.
-
DNA repair and resistance of gliomas to chemotherapy and radiotherapy.Mol Cancer Res. 2009 Jul;7(7):989-99. doi: 10.1158/1541-7786.MCR-09-0030. Mol Cancer Res. 2009. PMID: 19609002 Review.
-
Targeting homologous recombination repair defects in cancer.Trends Pharmacol Sci. 2010 Aug;31(8):372-80. doi: 10.1016/j.tips.2010.06.001. Epub 2010 Jul 2. Trends Pharmacol Sci. 2010. PMID: 20598756 Review.
Cited by
-
The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.Mol Cancer Res. 2012 Sep;10(9):1189-202. doi: 10.1158/1541-7786.MCR-11-0559. Epub 2012 Jul 16. Mol Cancer Res. 2012. PMID: 22802261 Free PMC article.
-
Nanomedicines for Overcoming Cancer Drug Resistance.Pharmaceutics. 2022 Aug 1;14(8):1606. doi: 10.3390/pharmaceutics14081606. Pharmaceutics. 2022. PMID: 36015232 Free PMC article. Review.
-
Ionizing radiation-induced foci persistence screen to discover enhancers of accelerated senescence.Int J High Throughput Screen. 2011 Mar;2:1-13. doi: 10.2147/IJHTS.S17076. Int J High Throughput Screen. 2011. PMID: 26097382 Free PMC article.
-
SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes.J Biomed Sci. 2019 Feb 18;26(1):20. doi: 10.1186/s12929-019-0510-4. J Biomed Sci. 2019. PMID: 30777052 Free PMC article.
-
The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells.Oncotarget. 2015 Dec 22;6(41):43944-63. doi: 10.18632/oncotarget.6267. Oncotarget. 2015. PMID: 26733491 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources